P/E společnosti Kazia Therapeutics
Jaká je hodnota metriky P/E společnosti Kazia Therapeutics?
Hodnota metriky P/E společnosti Kazia Therapeutics Limited je N/A
Jaká je definice metriky P/E?
P/E ratio je koeficient daný poměrem ceny akcie a příjmu společnosti na akcii za posledních 12 měsíců.
The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.
P/E společností v sektoru Health Care sektor na ASX ve srovnání se společností Kazia Therapeutics
Čemu se věnuje společnost Kazia Therapeutics?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Firmy s metrikou p/e podobnou společnosti Kazia Therapeutics
- Hodnota metriky P/E společnosti Big Ridge Gold je N/A
- Hodnota metriky P/E společnosti Babcock & Wilcox Enterprises Inc je N/A
- Hodnota metriky P/E společnosti Eurosport Active World je N/A
- Hodnota metriky P/E společnosti LOOPShare je N/A
- Hodnota metriky P/E společnosti Zenith Birla (India) je N/A
- Hodnota metriky P/E společnosti Codrus Minerals je N/A
- Hodnota metriky P/E společnosti Kazia Therapeutics je N/A
- Hodnota metriky P/E společnosti STI India je N/A
- Hodnota metriky P/E společnosti MIE je N/A
- Hodnota metriky P/E společnosti Granite Creek Copper je N/A
- Hodnota metriky P/E společnosti Beforepay Ltd je N/A
- Hodnota metriky P/E společnosti Vertu Capital je N/A
- Hodnota metriky P/E společnosti Nuchev je N/A